loader2
Partner With Us NRI

Ajanta Pharma Ltd share Price Today

Company details

2,373.00
2,404.40
1,273.65
2,540.00
6M Return 23.99%
1Y Return 81.10%
Mkt Cap.(Cr) 29,954.16
Volume 45,167
Div Yield 2.15%
OI
-
OI Chg %
-
Volume 45,167

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Muted numbers due to transitory issues, branded generics outlook upbeat..
About The Stock

    Ajanta Pharma is a focused player in branded generics, which constitutes ~72% of overall sales, spread across geographies including India.
    • As of Q4FY23, overall exports: domestic formulations ratio was at 67:33
    • Among exports, Asia accounts for ~41% of export formulations, Africa 26% and the US ~34%. The company also participates in anti-malarial tenders in
    Africa (included in Africa)

Q4FY23

    Muted Numbers on Revenue & Margins front
    • Revenues grew 1.3% YoY to ~₹ 882 crore mainly driven by Domestic business as well as US generics both of which grew ~17% YoY
    • EBITDA came in at ~ ₹ 150 crore, down ~28% YoY with margins at ~17%. Adjusted for forex loss margins were at ~20%
    • Adjusted PAT was at ~₹ 122 crore

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Ajanta Pharma announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue from operations at Rs 1,054 crore against Rs 882 crore; up 20%.
  • EBITDA at Rs 278 crore against Rs 149 crore; up 86%; EBITDA at 26%.
  • Profit after tax at Rs 203 crore against Rs 122 crore; up 66%; PAT at 19%.

FY24 Financial Highlights:

  • Revenue from operations at Rs 4,209 crore against Rs 3,743 crore; up 12%.
  • EBITDA at Rs 1,172 crore against Rs 783 crore; up 50%; EBITDA at 28%.
  • Profit after tax at Rs 816 crore against Rs 588 crore; up 39%; PAT at 19%.
  • Cashflow from operations (CFO) was Rs 785 crore, EBITDA to CFO conversion of 67%.
  • Free cashflow (FCF) was Rs 637 crore, FCF to PAT conversion of 78%.

Result PDF

View Other Company Results

Ajanta Pharma Ltd shares SWOT Analysis

Strengths (6)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Company with high TTM EPS Growth
  • Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Weakness (3)

  • MACD Crossover Below Signal Line
  • Decline in Net Profit (QoQ)
  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (1)

  • RSI indicating price strength

Threats (1)

  • Increasing Trend in Non-Core Income

Resistance and support

R1 2,397.9
R2 2,416.8
R3 2,429.3
Pivot

2,385.43

S1 2,366.5
S2 2,354.0
S3 2,335.1
EMA SMA
2,335.8
2,251.5
2,162.9
1,997.8
2,332.1
2,217.0
2,191.2
1,998.6
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
SOCIETE GENERALE Block Purchase 2024-01-25 2195.5 125617 BSE
MARSHALLWACEINVESTMENTSTRATEGIESMARKETNEUTRALTOPSFUND Block Purchase 2024-01-25 2195.5 47901 BSE
MARSHALL WACE INVESTMENT STRATEGIESGTOPS FUND Block Purchase 2024-01-25 2195.5 2685 BSE
Name Category Shares
Rajesh M Agrawal, trustee Rajesh Agrawal Trust PROMOTER 14.48%
Yogesh M Agrawal, trustee Yogesh Agrawal Trust PROMOTER 14.48%
Ravi P Agrawal, trustee Ravi Agrawal Trust PROMOTER 13.01%
Aayush M Agrawal, trustee Aayush Agrawal Trust PROMOTER 11.31%
Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal PROMOTER 2.68%
Gabs Investments Pvt Ltd PROMOTER 10%

OUR RESEARCH VIEW

Investment recommendation
Muted numbers due to transitory issues, branded generics outlook upbeat..
Call Date
06 May 2023
Entry Price 1,290.00
Target Price 1,520.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Ajanta Pharma Ltd Stocks COMPARISON

Financials( in Cr) Ajanta Pharma Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Zydus Lifesciences Ltd Divis Laboratories Ltd
Price 2,378.90 1,539.30 1,482.30 1,080.65 4,058.55
% Change -0.83 -0.11 2.77 -0.71 1.05
Mcap Cr 29,954.16 369,329.64 119,676.01 108,738.68 107,741.92
Revenue TTM Cr 3,742.64 43,885.68 15,790.60 17,237.40 7,767.51
Net Profit TTM Cr 587.98 8,560.84 2,513.47 1,997.30 1,823.38
PE TTM 36.70 39.39 28.09 28.10 77.94
1 Year Return 81.10 64.20 60.26 113.46 24.30
ROCE 22.21 16.79 14.76 16.25 19.30
ROE 17.68 16.46 10.66 14.05 14.89
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 3,387.99 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 41,960.24 -29,509.50
LAST 3M 102,987.80 -35,737.56
LAST 6M 169,824.52 46,518.61
LAST 12M 263,691.56 126,663.80

Ajanta Pharma Ltd Information

Stock PE (TTM)
36.7
Promoter Holding
66.21%
Book Value
283.3043
ROCE
22.21%
ROE
17.68%
Description
  • Ajanta Pharma Limited is in the business of manufacturing and marketing speciality pharmaceutical dosages. The company operates in domestic and various international markets, producing a range of products in therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, paediatric, orthopaedic, respiratory, and cardiology. The company has its headquarters in Mumbai and offices in the USA, Mauritius, and the Philippines. The company was incorporated in 1979, and its market capitalisation, as of 9 October 2022, is Rs 16,148 crore.

    The company is listed on the National Stock Exchange (NSE) under code AJANTPHARM and on the Bombay Stock Exchange (BSE) under code 532331.

    Ajanta Pharma Limited currently sells its products in more than 30 countries across the world and has seven state-of-the-art manufacturing facilities in India. The company’s R&D centre has more than 750 scientists who are developing innovative pharmaceutical products for global markets. Over the years, the company has developed a specialisation in developing generic medicines and process chemistry for domestic as well as international markets.

    In June 2022, the shareholding pattern of Ajanta Pharma Limited revealed a 70.48% stake by promoters, 10.88% stake in mutual funds, 9.30% stake by retail investors, 8.30% stake by Foreign Institutional Investors, and 1.04% stake by other domestic institutions. The management team of the company includes  Mr  Mannalal B Agarwal (Chairman),  Mr  Madhusudan B Agarwal (Vice-Chairman),  Mr  Yogesh Agarwal (Managing Director),  Mr  Chandrakant M Khetan (Independent Director), and  Mr  Gaurang Shah (Company Secretary), among others.

    On 10 October 2022, Ajanta Pharma Limited’s share price closed at Rs 1268.80 at the NSE and Rs 1263.55 at the BSE. The share’s 52-week low and 52-week high prices are Rs 1061.77 and Rs 1577.20, respectively. Ajanta Pharma shares have provided a six-month return of 9.11% and its PE ratio as of 10 October 2022 stood at 22.65, while the PB ratio stood at 0.20. If you want to invest in Ajanta Pharma shares, you can open a demat account with ICICIdirect and place your orders.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose

Registered Address

Ajanta House, Charkop Kandivli (W), Mumbai, Maharashtra, 400067

Tel : 91-22-66061000/1204/1203
Email : info:ajantapharma.com; investorgrievance:ajantapha
Website : http://www.ajantapharma.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 532331
NSE Code : AJANTPHARM
Book Closure Date (Month) :
BSE Group : A
ISIN : INE031B01049

FAQ’s on Ajanta Pharma Ltd Shares

You can buy Ajanta Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Ajanta Pharma Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 22, 2024 03:59 PM the closing price of Ajanta Pharma Ltd was Rs.2,378.90.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 22, 2024 03:59 PM, the market cap of Ajanta Pharma Ltd stood at Rs. 29,954.16.

The latest PE ratio of Ajanta Pharma Ltd as of May 22, 2024 03:59 PM is 36.70

The latest PB ratio of Ajanta Pharma Ltd as of May 22, 2024 03:59 PM is 0.12

The 52-week high of Ajanta Pharma Ltd share price is Rs. 2,540.00 while the 52-week low is Rs. 1,273.65

According to analyst recommendations, Ajanta Pharma Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app